Search

Halozyme Therapeutics Inc

Suletud

SektorTervishoid

75.78 1.12

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

73.6

Max

76.04

Põhinäitajad

By Trading Economics

Sissetulek

292M

150M

Müük

-75M

377M

P/E

Sektori keskmine

26.737

60.149

Aktsiakasum

1.221

Kasumimarginaal

39.832

Töötajad

423

EBITDA

-62M

220M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+7.93% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. aug 2026

Turustatistika

By TradingEconomics

Turukapital

1.4B

9B

Eelmine avamishind

74.66

Eelmine sulgemishind

75.78

Uudiste sentiment

By Acuity

8%

92%

5 / 342 Pingereas Healthcare

Halozyme Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. juuli 2026, 23:52 UTC

Correlated Moves
Social Media
News

Western Digital shares fell after hours, closing at about $513.97. Option traders showed bearish sentiment, with puts outpacing calls in volume.

15. juuli 2026, 23:26 UTC

News

Synopsys shares are higher in after-market hours following a Buy rating from analyst Gary Mobley, who set a price target of $570.

15. juuli 2026, 23:16 UTC

Social Media
News

PayPal Holdings Inc. shares are lower in after-market trading amid uncertainty over a $53 billion acquisition offer from Stripe and Advent International.

15. juuli 2026, 23:11 UTC

Correlated Moves
News

The CHF/HKD exchange rate is trading higher, influenced by a decline in the US Producer Price Index and a stronger NY Empire State Manufacturing Index.

15. juuli 2026, 23:06 UTC

Social Media
News

Wedbush initiates coverage on eBay with an Outperform rating. Shares are higher in after-hours trading following positive sentiment and acquisition news.

15. juuli 2026, 23:06 UTC

News

American Airlines Group shares are lower in after-market hours following the appointment of John W. Dietrich to its board amid rising fuel price concerns.

15. juuli 2026, 23:06 UTC

News

Vanguard Total Bond Market ETF is slightly higher in after-market hours, reflecting cautious investor sentiment amid escalating Middle East tensions and oil supply concerns.

15. juuli 2026, 23:02 UTC

News
Social Media
Event

United Airlines Holdings shares fell in after-hours trading despite reporting strong second-quarter earnings of $1.99 per share and revenue of $17.67 billion.

15. juuli 2026, 23:01 UTC

Social Media
News

J.B. Hunt Transport Services shares rose in after-market trading following strong second-quarter results, with revenues up 19% to $3.50 billion and EPS of $1.91.

15. juuli 2026, 23:01 UTC

News

Wedbush initiated coverage on Booking Holdings with an Outperform rating. Shares are higher in after-market trading following a close at $174.85.

15. juuli 2026, 22:16 UTC

News

Micron Technology will participate in the KeyBanc Capital Markets Technology Leadership Forum on August 10, 2026. Shares are higher in after-hours trading.

15. juuli 2026, 20:14 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Large-Cap ETF is lower in after-market hours, influenced by slight declines in major holdings like Microsoft and Apple amid mixed U.S. equity performance.

15. juuli 2026, 20:07 UTC

News

Bitcoin's price is declining amid broader market sentiment shifts following softer inflation readings. Geopolitical tensions may also be influencing the cryptocurrency market.

15. juuli 2026, 20:07 UTC

News
Correlated Moves

Microchip Technology shares are lower today, following a broader Nasdaq decline. Ongoing U.S.-Iran tensions continue to affect overall investor sentiment.

15. juuli 2026, 20:07 UTC

News

Ethereum is trading higher, continuing an upward trend since Tuesday. The U.S. Producer Price Index decline has eased inflation concerns and boosted market sentiment.

15. juuli 2026, 20:07 UTC

News

Bitcoin's price is lower today, influenced by softer inflation data and ongoing geopolitical tensions, despite earlier gains above Tuesday's close.

15. juuli 2026, 20:06 UTC

News

Charter Communications shares rose following Liberty Broadband's $17.65 million insider sale of 129,907 shares, despite a recent revenue decline.

15. juuli 2026, 20:03 UTC

Social Media
News

Amazon.com Inc is higher today, driven by a partnership with Herotel for satellite internet services and leadership changes within Amazon Web Services.

15. juuli 2026, 20:02 UTC

Social Media
News
Macro Event

CSX shares are lower as Benchmark cuts its price target to $4 from $48, while Citizens initiates coverage with a Market Perform rating.

15. juuli 2026, 20:02 UTC

News

Cisco Systems Inc shares are lower, hitting a nine-week low of 111.29 USD amid a broader decline in the Communications Equipment sub-sector.

15. juuli 2026, 20:02 UTC

News

Workday Inc. shares are higher, supported by positive sentiment after a drop in the U.S. Producer Price Index, easing inflation concerns and interest rate hike expectations.

15. juuli 2026, 20:02 UTC

Social Media
News

Apple Inc. shares rose after regulatory approval for its generative AI service in China and Citibank's price target increase to $365 amid market challenges.

15. juuli 2026, 20:02 UTC

Correlated Moves
News
Macro Event
Social Media

Lam Research shares are lower as the Semiconductor Materials & Equipment sector declines. UBS raised its price target to $435, despite negative sentiment from insider selling.

15. juuli 2026, 20:02 UTC

Social Media
Macro Event
Event
News

Cintas Corp's stock rises following strong fiscal fourth-quarter results, with revenue of $2.91 billion and GAAP EPS of $1.26 exceeding analyst expectations.

15. juuli 2026, 20:02 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials Inc shares are lower today amid mixed assessments, despite UBS raising its price target to $705. The stock's recent surge raises investor caution.

15. juuli 2026, 19:56 UTC

News
Social Media

Broadcom faces EU scrutiny over VMware practices, yet shares are higher amid positive sentiment for hardware makers and AI demand.

15. juuli 2026, 19:56 UTC

News
Social Media

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims following extended loan term disclosures.

15. juuli 2026, 19:56 UTC

News

Electronic Arts is rising amid reports of increased confidence in regulatory approval for its $55 billion acquisition at $210 per share.

15. juuli 2026, 19:53 UTC

News
Social Media
Macro Event

Microsoft shares are higher today as Evercore ISI raised its price target to $525. Analysts remain optimistic ahead of the upcoming earnings report.

15. juuli 2026, 19:52 UTC

News
Social Media

Alphabet Inc shares are higher, boosted by Warren Buffett's endorsement and plans for third-party stores in its App Store. Anticipation for earnings also supports momentum.

Võrdlus sarnastega

Hinnamuutus

Halozyme Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

7.93% tõus

12 kuu keskmine prognoos

Keskmine 81 USD  7.93%

Kõrge 96 USD

Madal 57 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Halozyme Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

3

Osta

2

Hoia

1

Müü

Sentiment

By Acuity

5 / 342 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat